Summary
ANGLE Plc (ANGLE) is a medical diagnostic company that offers cancer diagnostics and fetal health products. Its products include parsortix PC1 system, portrait+ CTC staining kit, immunofluorescence kits, among others. It offers translation research and laboratory services. The company develops products for use in rare cell diagnostics that enable early, accurate identification of an individual’s condition for the prevention, treatment and monitoring of disease. Its harvested CTCs have a range of applications such as diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness and remission monitoring. The company has operations in the US and the UK. ANGLE is headquartered in Guildford, Surrey, the UK.This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company ANGLE Plc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- ANGLE Plc Company Overview
- ANGLE Plc Company Snapshot
- ANGLE Plc Pipeline Products and Ongoing Clinical Trials Overview
- ANGLE Plc - Pipeline Analysis Overview
- ANGLE Plc - Key Facts
- ANGLE Plc - Major Products and Services
- ANGLE Plc Pipeline Products by Development Stage
- ANGLE Plc Ongoing Clinical Trials by Trial Status
- ANGLE Plc Pipeline Products Overview
- ALENA System - Abscesses
- ALENA System - Abscesses Product Overview
- ALENA System - Antibiotic Resistance
- ALENA System - Antibiotic Resistance Product Overview
- ALENA System - Bone & Joint Infections
- ALENA System - Bone & Joint Infections Product Overview
- ALENA System - Sepsis
- ALENA System - Sepsis Product Overview
- Cardiac Troponin Biomarker Kit
- Cardiac Troponin Biomarker Kit Product Overview
- HyCEAD Ziplex System - Ovarian Cancer Assay
- HyCEAD Ziplex System - Ovarian Cancer Assay Product Overview
- Landscape+ Ovarian Assay
- Landscape+ Ovarian Assay Product Overview
- LDT - Renal Cell Carcinoma Signature
- LDT - Renal Cell Carcinoma Signature Product Overview
- Multiplex Ovarian Cancer Biomarker Assay
- Multiplex Ovarian Cancer Biomarker Assay Product Overview
- Multiplex Pathogen Detection Test
- Multiplex Pathogen Detection Test Product Overview
- Parsortix GEN2
- Parsortix GEN2 Product Overview
- Parsortix System - Renal Carcinoma
- Parsortix System - Renal Carcinoma Product Overview
- Parsortix-Based Test - Brain Metastasis
- Parsortix-Based Test - Brain Metastasis Product Overview
- Parsortix-Based Test - Colorectal Cancer
- Parsortix-Based Test - Colorectal Cancer Product Overview
- Parsortix-Based Test - Head & Neck Cancer
- Parsortix-Based Test - Head & Neck Cancer Product Overview
- Parsortix-Based Test - Lung Cancer
- Parsortix-Based Test - Lung Cancer Product Overview
- Parsortix-Based Test - Pancreatic Cancer
- Parsortix-Based Test - Pancreatic Cancer Product Overview
- Parsortix-Based Test - Prostate Cancer
- Parsortix-Based Test - Prostate Cancer Product Overview
- Parsortix-Based Test - Prostate Cancer Clinical Trial
- Point-Of-Care Diagnostic Test - TBI
- Point-Of-Care Diagnostic Test - TBI Product Overview
- Portrait HER2 Assay
- Portrait HER2 Assay Product Overview
- Portrait HER2 Assay Clinical Trial
- Rapid Blood Test - Intracranial Hemorrhage
- Rapid Blood Test - Intracranial Hemorrhage Product Overview
- ANGLE Plc - Key Competitors
- ANGLE Plc - Key Employees
- ANGLE Plc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- ANGLE Plc, Recent Developments
- Oct 17, 2024: Angle Publication Demonstrates Potential for Multi-marker CTC Profiling in Early Prostate Cancer
- Sep 26, 2024: 100th Publication Supporting Parsortix System Use
- Sep 23, 2024: Angle PLC Announces Exclusive Agreement for DNA NGS Panel
- Sep 19, 2024: ANGLE : Agreement With Recursion Pharmaceuticals for Parsortix CTC analysis
- Aug 22, 2024: Angle PLC - Data Supporting FDA Approval Published in Journal
- Aug 01, 2024: Independent Parsortix Study Highlights Benefits of Combined Dna Analysis in Melanoma
- Jun 11, 2024: Parsortix System and Assays Being Showcased at the 2024 Annual Congress of the European Association for Cancer Research
- Jun 11, 2024: Angle Announces Parsortix and Assays Being Showcased at EACR 2024
- May 16, 2024: Angle Announces Study of Ovarian Cancer CTCs Using Parsortix
- May 03, 2024: Angle Announces New Commercial Agreement with Large Pharma
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- ANGLE Plc Pipeline Products and Ongoing Clinical Trials Overview
- ANGLE Plc Pipeline Products by Equipment Type
- ANGLE Plc Pipeline Products by Indication
- ANGLE Plc Ongoing Clinical Trials by Trial Status
- ANGLE Plc, Key Facts
- ANGLE Plc, Major Products and Services
- ANGLE Plc Number of Pipeline Products by Development Stage
- ANGLE Plc Pipeline Products Summary by Development Stage
- ANGLE Plc Ongoing Clinical Trials by Trial Status
- ANGLE Plc Ongoing Clinical Trials Summary
- ALENA System - Abscesses - Product Status
- ALENA System - Abscesses - Product Description
- ALENA System - Antibiotic Resistance - Product Status
- ALENA System - Antibiotic Resistance - Product Description
- ALENA System - Bone & Joint Infections - Product Status
- ALENA System - Bone & Joint Infections - Product Description
- ALENA System - Sepsis - Product Status
- ALENA System - Sepsis - Product Description
- Cardiac Troponin Biomarker Kit - Product Status
- Cardiac Troponin Biomarker Kit - Product Description
- HyCEAD Ziplex System - Ovarian Cancer Assay - Product Status
- HyCEAD Ziplex System - Ovarian Cancer Assay - Product Description
- Landscape+ Ovarian Assay - Product Status
- Landscape+ Ovarian Assay - Product Description
- LDT - Renal Cell Carcinoma Signature - Product Status
- LDT - Renal Cell Carcinoma Signature - Product Description
- Multiplex Ovarian Cancer Biomarker Assay - Product Status
- Multiplex Ovarian Cancer Biomarker Assay - Product Description
- Multiplex Pathogen Detection Test - Product Status
- Multiplex Pathogen Detection Test - Product Description
- Parsortix GEN2 - Product Status
- Parsortix GEN2 - Product Description
- Parsortix System - Renal Carcinoma - Product Status
- Parsortix System - Renal Carcinoma - Product Description
- Parsortix-Based Test - Brain Metastasis - Product Status
- Parsortix-Based Test - Brain Metastasis - Product Description
- Parsortix-Based Test - Colorectal Cancer - Product Status
- Parsortix-Based Test - Colorectal Cancer - Product Description
- Parsortix-Based Test - Head & Neck Cancer - Product Status
- Parsortix-Based Test - Head & Neck Cancer - Product Description
- Parsortix-Based Test - Lung Cancer - Product Status
- Parsortix-Based Test - Lung Cancer - Product Description
- Parsortix-Based Test - Pancreatic Cancer - Product Status
- Parsortix-Based Test - Pancreatic Cancer - Product Description
- Parsortix-Based Test - Prostate Cancer - Product Status
- Parsortix-Based Test - Prostate Cancer - Product Description
- Parsortix-Based Test - Prostate Cancer - Study to Investigate the Parsortix System for the Detection of Prostate Cancer and Prediction of its Severity
- Point-Of-Care Diagnostic Test - TBI - Product Status
- Point-Of-Care Diagnostic Test - TBI - Product Description
- Portrait HER2 Assay - Product Status
- Portrait HER2 Assay - Product Description
- Portrait HER2 Assay - An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an Anti-human Epidermal Growth Factor Receptor 2 (Anti-HER2) Antibody-drug Conjugate (ADC), in Previously Treated Subjects With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
- Rapid Blood Test - Intracranial Hemorrhage - Product Status
- Rapid Blood Test - Intracranial Hemorrhage - Product Description
- ANGLE Plc, Key Employees
- ANGLE Plc, Subsidiaries
- Glossary
- ANGLE Plc Pipeline Products by Equipment Type
- ANGLE Plc Pipeline Products by Development Stage
- ANGLE Plc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3M Health Care Ltd
- Sekisui Diagnostics UK Ltd
- ConvaTec Group Plc
- Artivion Inc
- Advanced Medical Solutions Group Plc
